Needham & Company Reiterates Avadel Pharmaceuticals (AVDL) at Buy with $15 PT, "Incrementally More Positive on AVDL" Following Recent Management Chat
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $15.00 price target on Avadel Pharmaceuticals (NASDAQ: AVDL), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
